Revenue at Irish engineer Mincon ahead of last year Group says sea freight lead times ‘remain challenging’ due to pandemic
Mon, May 10, 2021, 07:13 Updated: Mon, May 10, 2021, 18:14
Revenue at Irish engineering group Mincon is currently ahead of last year for the first four months, the company said in a trading update on Monday.
The group, which specialises in the design, manufacture, sale and servicing of rock-drilling tools and associated products, said it was experiencing “good order levels in most markets, with a positive momentum building across the business”.
Sea freight lead times “remain challenging” due to the pandemic, and the company is using air freight where necessary to overcome these freight challenges. “We curtailed other overheads to compensate for any increased freight costs,” it said.
AVECTAS Leads €7.23 million Consortium Awarded Part Funding From Ireland’s Disruptive Technologies Innovation Fund
Funding to develop high throughput cell engineering technology to manufacture off the shelf cell therapies
Project, led by Avectas in partnership with Bluebridge Technologies and National Institute for Bioprocessing Research and Training (NIBRT), would support Ireland s goal of being at the forefront of cell therapy manufacturing
Kildare, Ireland and Cambridge, MA, USA … Friday 23 April 2021. Irish cell engineering company, Avectas, is leading a consortium which will invest €7.23 million, including €4.4 million awarded under the Irish Government’s Disruptive Technology Innovation Fund (DTIF), to develop a high-throughput scale of its proprietary cell engineering platform Solupore®. With consortium partners Bluebridge Technologies and NIBRT, the project expands Avectas development towards commercialising an advanced large-scale, digitalised cell engin
Share this article
Share this article
DUBLIN, April 22, 2021 /PRNewswire/ Irish cell engineering company, Avectas, is leading a consortium which will invest €7.23 million, including €4.4 million awarded under the Irish Government s Disruptive Technology Innovation Fund (DTIF), to develop a high-throughput scale of its proprietary cell engineering platform Solupore®. With consortium partners Bluebridge Technologies and NIBRT, the project expands Avectas development towards commercialising an advanced large-scale, digitalised cell engineering platform optimised to manufacture off-the-shelf cell-based therapies for cancer treatment.
The Disruptive Technologies Innovation Fund (DTIF) is a €500 million fund established under Project Ireland 2040 and run by the Department of Enterprise Trade and Employment with support from Enterprise Ireland.
Dublin company Akkure Genomics crowdfunds its way to €1.2m
Prof Oran Rigby, CEO and co-founder of Akkure Genomics. Image: Paul Sharp/SharpPix
Akkure Genomics will use its latest funding round to support an expansion of its clinical trials platform.
Akkure Genomics launched a crowdfunding campaign on Spark Crowdfunding in late January. The plan was to run a 35-day campaign to reach a €500,000 target. Within one week, the company had passed €1m in crowdfunding.
The campaign has now closed with €1.2m raised by more than 300 investors. The scaling digital health company will use this funding to accelerate the roll-out of its clinical trials platform. It is targeting a US launch in the next 12 to 18 months, which this funding will support.